contact@carpem.fr

Concept du programme

Carpem > Programmes > De la cellule au traitement > Concept du programme

illustration2damierbis

 

Program coordinated by Pr E. Tartour

TUMOR MICROENVIRONMENT AND IMMUNITY

The main aim of this project is to establish a bridge between the comprehensive analysis of the tumor microenvironment in three human tumours (colon, head and neck and lung carcinoma) and the identification of relevant biomarkers predicting the clinical outcome of patients and/or the response to various cancer therapies. In addition, development of innovative therapeutics for cancer patients will benefit of a better knowledge of the tumor microenvironment and of the availability of original preclinical models and of novel immunomodulators shared by the partners. An extension of these projects involves application of similar approaches to the analysis of tumoral and peritumoral lymphoid cells in lymphnodes from immuno-competent and immunodeficient individuals.

1/ Exploring the tumor microenvironment

  • Integrative biology and innovative tools for the analysis of tumor microenvironment
  • Focusing of some particularity of immune cells in the tumor microenvironment (adaptative and innate immune cells, tertiary lymphoid structure, suppressive and anergic cells…)
  • Psychosocial risk factors and cancer: links between chronic depression, inflammation and cancer
  • Deciphering immunogenic tumor cell death
  • Tumor immunity in melanoma patients and in an original preclinical spontaneous melanoma model

2/  From the analysis of tumor microenvironment to the identification of novel type of biomarkers

  • Biomarkers associated with prognosis (overall survival, PFS…): towards new classification of tumors (value for the stratification of patients in clinical trials)
  • Theranostic biomarkers for the prediction of therapeutic response to chemotherapy, antiangiogenic, targeted therapy

3/ Development of innovative biotherapies based on a better understanding between tumor-host interaction and the sharing of original preclinical models

  • Therapeutic cancer vaccines combined with antagonist molecules to overcome immunosuppression or anergy present in the tumor microenvironement of head and neck cancer
  • How to exploit immunomodulation mediated by antiangiogenic molecules in clinical trials?
  • Modulation of endogenous oxidative stress or expression of mutated CYP450 to increase the potency of chemotherapy
  • Improving antibody therapy by the recruitment of adaptative immunity